CICC: Upgraded ASM Pacific Technology Ltd. (00522) target price to HKD 98, maintaining "Outperform" rating.
Considering that ASMPT was impacted by a one-time project in the third quarter of this year, the group has lowered its earnings per share forecast for 2025 by 89%. Due to conservative assumptions on gross profit margin and operating expenses, forecasts for 2026-2027 have been lowered by 33%/10% respectively. At the same time, the forecast for earnings per share for 2025-2027 has been lowered by 3%.
Bank of China International released a research report stating that the importance of advanced packaging in integrated circuit production is increasing, and ASMPT (00522) holds a leading position in its equipment field. The bank has raised its target price-to-book ratio from the expected 2.3 times in 2026 to 2.5 times, corresponding to a 9% increase in the target price from HK$90 to HK$98. The bank believes that ASMPT, as a semiconductor packaging equipment manufacturer with strong advanced packaging capabilities, is a high-quality stock for long-term investment, especially in the context where advanced packaging is becoming increasingly crucial for IC miniaturization. Therefore, the bank maintains its "outperform the market" rating.
Considering that ASMPT was affected by a one-time project in the third quarter of this year, the group's earnings forecast for 2025 has been lowered by 89% per share. Due to conservative assumptions on gross margin and operating expenses, the forecast for 2026-2027 has been adjusted downwards by 33%/10%. At the same time, the forecast for net asset value per share (BVPS) for 2025-2027 has been revised downwards by 3%.
 Related Articles 

Sino Medical Sciences Technology Inc. (688108.SH): Spinal Fracture Balloon Product Obtains Foreign Medical Device Registration Certificate.

Bank of America Securities: Raise Weichai Power (02338) target price to 21.5 Hong Kong dollars, third-quarter net profit beats expectations.

Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary receives registration certificate for Butorphanol Tartrate Injection.
Sino Medical Sciences Technology Inc. (688108.SH): Spinal Fracture Balloon Product Obtains Foreign Medical Device Registration Certificate.

Bank of America Securities: Raise Weichai Power (02338) target price to 21.5 Hong Kong dollars, third-quarter net profit beats expectations.

Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary receives registration certificate for Butorphanol Tartrate Injection.

RECOMMEND

First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025

Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025

Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025


